Too big to succeed? Haven dissolves with experts saying it never had a defined strategy
The joint effort by Amazon, Berkshire Hathaway and JPMorgan Chase to lower costs and provide better healthcare for their employees, will dissolve in February.
The joint effort by Amazon, Berkshire Hathaway and JPMorgan Chase to lower costs and provide better healthcare for their employees, will dissolve in February.
Dr. Atul Gawande, CEO of Haven, stepped down from the high-profile healthcare venture to focus on Covid-19. He will become chairman of the company while it searches for a new CEO.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Dana Gelb Safran, a Blue Cross Blue Shield of Massachusetts executive who works on analytics and improving outcomes, will serve as the initiative's "head of measurement," according to CNBC.
During an event Rock Health Summit in San Francisco, the always quotable Cosgrove shared his thoughts on topics ranging from the V.A. to Theranos to EMRs to where he believed big tech firms can hope to change healthcare.
The yet-unnamed Amazon-Berkshire Hathaway-J.P. Morgan healthcare venture has selected Jack Stoddard, who previously was Comcast's general manager of digital health, as its chief operating officer.
Effective July 9, surgeon and author Atul Gawande, who has been outspoken about healthcare costs and quality, will take over as CEO of the new initiative.
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.
According to a CNBC report, the three companies have shifted to looking for a candidate with a bit more entrepreneurial experience.
Lack of innovation has contributed to the industry’s failure to drive down the cost curve and regardless of how Amazon/Berkshire/JP Morgan moves forward, other large employers will be anxious to leverage any programs that successfully lower costs.
Many industry experts are expressing doubts about the Amazon/Berkshire/JP Morgan healthcare initiative, but large employers who self-insure their employee benefits have historically been at the forefront of adopting new innovations.
The companies want to build technology solutions that will cut healthcare costs but even though it is early days for the joint venture, the news has rattled the market and sent health insurer share prices tumbling.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.